Ja. Foekens et al., EXPRESSION OF TUMOR-ASSOCIATED 90K-ANTIGEN IN HUMAN BREAST-CANCER - NO CORRELATION WITH PROGNOSIS AND RESPONSE TO FIRST-LINE THERAPY WITH TAMOXIFEN, International journal of cancer, 64(2), 1995, pp. 130-134
It has been shown that a 90-kDa protein (90K), with an as yet unknown
function, is expressed in the majority of human breast-cancer tissues.
In addition, the serum level of this 90K antigen is elevated in a cer
tain proportion of breast-cancer patients, and high serum levels are a
ssociated with a poor overall survival. It was therefore of interest t
o determine whether levels of 90K in tumor tissues could be used as a
prognostic variable in breast cancer. In the present study, the levels
of 90K in primary breast tumor cytosols were studied with respect to
the length of relapse-free or overall survival in 547 patients (median
follow-up, 81.4 months), and the relationship with response to first-
line tamoxifen therapy and the length of progression-free survival in
184 patients with recurrent disease (median follow-up, 59.8 months). 9
0K levels in tumor cytosols were determined with an immunoradiometric
assay. The cytosolic contents of 90K were not significantly correlated
with age, menopausal status, tumor size, nodal status or differentiat
ion grade. On the other hand, the levels of 90K were positively correl
ated with those of cytosolic estrogen receptor, progesterone receptor,
urokinase-type plasminogen activator, its inhibitor PAI-1, cathepsin
D and PSZ. The cytosolic tumor level of 90K was not associated with th
e rate of relapse or death in primary breast cancer, nor with response
to first-line therapy with tamoxifen or the length of progression-fre
e survival in recurrent disease. (C) 1995 Wiley-Liss, Inc.